KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Depreciation and Depletion (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Depreciation and Depletion for 8 consecutive years, with $21000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion fell 22.22% year-over-year to $21000.0, compared with a TTM value of $100000.0 through Dec 2025, up 58.73%, and an annual FY2025 reading of $100000.0, up 58.73% over the prior year.
  • Depreciation and Depletion was $21000.0 for Q4 2025 at Esperion Therapeutics, down from $26000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $153000.0 in Q1 2021 and bottomed at $6000.0 in Q4 2023.
  • Average Depreciation and Depletion over 5 years is $75736.8, with a median of $51000.0 recorded in 2023.
  • The sharpest move saw Depreciation and Depletion crashed 93.48% in 2023, then soared 350.0% in 2024.
  • Year by year, Depreciation and Depletion stood at $153000.0 in 2021, then crashed by 39.87% to $92000.0 in 2022, then plummeted by 93.48% to $6000.0 in 2023, then skyrocketed by 350.0% to $27000.0 in 2024, then dropped by 22.22% to $21000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for ESPR at $21000.0 in Q4 2025, $26000.0 in Q3 2025, and $27000.0 in Q2 2025.